Registered title, quoted from ClinicalTrials.gov
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Xuzhou Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05323201, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Subjects must have histologically or cytologically confirmed unresectable, recurrent and / or metastatic hepatocellular carcinoma (HCC). And tumor tissues are measured positive for B7H3 expression.
Inclusion criterion 4
The subject has received chemotherapy/radiotherapy within the past 4 weeks.
Exclusion criterion 9
The subjects have infectious diseases (such as HIV, syphilis, active tuberculosis, etc.);
Exclusion criterion 2
The subject is a pregnant or lactating woman.
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05323201, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subjects should be 18-70 years old.
- Subject has adequate performance status as defined by ECOG score of≤ 2.
- Expected life expectancy is no less than 12 weeks.
- Subjects must have histologically or cytologically confirmed unresectable, recurrent and / or metastatic hepatocellular carcinoma (HCC). And tumor tissues are measured positive for B7H3 expression.
- Child-Pugh A, B grade.
- Blood routine:
white blood cell count≥ 2.5 × 10\^9 / L; hemoglobin≥ 9 g/dL; platelet count≥ 50 × 10\^9 / L; lymphocyte proportion≥ 15 %;
- Adequate organ function. Patients' main organs ( heart, lung, liver, kidney, etc. ) function well:
ALT and AST≤ 5 × ULN; ALB≥ 30 g/L; Total bilirubin≤ 2.5 × ULN; Serum creatinine< 220μmol/L; Indoor oxygen saturation ≥ 95 %; Left ventricular ejection fraction≥ 40%;
- No allergic reaction to contrast agents.
- Procurement and T-cell production eligibility: a previously evaluation confirmed autologous peripheral blood mononuclear cells can be used for T-cell production.
- Patients or their legal guardians voluntarily participate in and sign the informed consent form.
Exclusion Criteria:
- The subject is a pregnant or lactating woman.
- The subjects have infectious diseases (such as HIV, syphilis, active tuberculosis, etc.);
- The subject has active infection or coagulation dysfunction.
- Subjects with previous hepatic encephalopathy.
- The subject is on anticoagulation or antiplatelet therapy.
- The subject is an organ transplant or waiting for transplant.
- Subjects with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation.
- The subjects are highly allergic or have a history of severe allergies.
- The subject has received chemotherapy/radiotherapy within the past 4 weeks.
- The subject has a history of cellular immunotherapy or antibody therapy.
- The subject is receiving systemic hormone therapy.
- Subjects with systemic infection or severe local infection requiring anti-infection treatment.
- The subject has dysfunction of important organs such as heart, lung, brain, liver, and kidney.
- The subject is participating in other clinical research.
- The doctor believes that there are other reasons not to be included in the treatment.
- Unwilling or unable to provide consent/assent for participation in the study.
Quoted from ClinicalTrials.gov, NCT05323201, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05323201, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.